Published in Clin Med Insights Endocrinol Diabetes on July 29, 2014
Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. BMC Med (2017) 0.75
Regulation of bone formation by baicalein via the mTORC1 pathway. Drug Des Devel Ther (2015) 0.75
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Endocrine regulation of energy metabolism by the skeleton. Cell (2007) 10.41
Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A (2008) 4.77
Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev (1989) 3.87
Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab (2008) 2.84
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation (2008) 2.44
Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab (2008) 2.30
Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res (2009) 2.20
Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures. Proc Natl Acad Sci U S A (2011) 1.67
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab (2000) 1.45
Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta (2008) 1.43
Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone (2010) 1.22
Sex steroids and vascular responses in hypertension and aging. Gend Med (2008) 1.04
Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol (2008) 1.03
Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res (2013) 1.03
The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. Thyroid (2008) 1.01
Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. Gynecol Endocrinol (2003) 1.01
Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men. BMC Endocr Disord (2011) 0.97
Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women. Maturitas (2009) 0.94
Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population--the Tromsø study. J Thromb Haemost (2010) 0.88
Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. Diabetes Care (2013) 0.87
Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clin Endocrinol (Oxf) (1993) 0.87
The relationship between regional abdominal fat distribution and both insulin resistance and subclinical chronic inflammation in non-diabetic adults. Diabetol Metab Syndr (2014) 0.86
Role of serum FSH measurement on bone resorption in postmenopausal women. Endocrine (2011) 0.86
No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells. Mol Cell Endocrinol (2012) 0.85
Subclinical hyperthyroidism of variable etiology and its influence on bone in postmenopausal women. Hormones (Athens) (2007) 0.84
Undercarboxylated osteocalcin does not correlate with insulin resistance as assessed by euglycemic hyperinsulinemic clamp technique in patients with type 2 diabetes mellitus. Diabetol Metab Syndr (2012) 0.82
Interleukin-6 and its considerable role in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in postmenopausal women. Endokrynol Pol (2011) 0.81
Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J Clin Endocrinol Metab (2005) 0.79
Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. Thyroid (2003) 0.78
A possible role of osteocalcin in the regulation of insulin secretion: human in vivo evidence? J Endocrinol (2008) 0.78
Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women. Eur J Endocrinol (2007) 0.77
Serum under-carboxylated osteocalcin levels in women with polycystic ovary syndrome: weight-dependent relationships with endocrine and metabolic traits. J Ovarian Res (2013) 0.77
Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol (2005) 0.77